Postdialysis outcomes associated with consistent anemia treatment in predialysis patients with chronic kidney disease

Clinical Nephrology

Volumn 69, Issue 4, 2008, Pages 251-259

  Wish, Jay B ^a   Nassar, G M ^b   Schulman, K ^c   del Aguila, M ^d   Provenzano, R ^e  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b Renal Research Inc   (United States)

^c MEDSTAT GROUP   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Anemia; CKD; ESA; Hemodialysis; Postdialysis outcomes

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; INSULIN; SULFONYLUREA;

ACUTE HEART INFARCTION; ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 42049100108     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP69251     Document Type: Article

References (23)

1. Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, Port FK, Gillespie BW, Predictors of early mortality among incident US hemo-dialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol. 2007; 2: 89-99.
2. Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev. 2005; CD003266.
3. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant. 2003; 18 (Suppl 2): ii2-ii6.
4. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41: 1-12.
5. Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin. 2005; 21: 981-987.
6. Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis. 2001; 37: 348-355.
7. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996; 28: 53-61.
8. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001; 16: 307-312.
9. Khan SS, Kazmi WH, Abichandani R, Tighiouart H, Pereira BJ, Kausz AT. Health care utilization among patients with chronic kidney disease. Kidney Int. 2002; 62: 229-236.
10. Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis. 2006; 48: S1-106.
11. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int. 2006; 69: 560-564.
12. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997; 77: 176-185.
13. London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis. 2002; 40: 539-548.
14. Lu WX Jones-Burton C, Zhan M, Salzberg DJ, Moore J Jr, Fink JC. Survival benefit of recombinant human erythropoietin administration prior to onset of endstage renal disease: variations across surrogates for quality of care and time. Nephron Clin Pract. 2005; 101: c79-86.
15. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M. The prevalence of anemia inpatients with chronic kidney disease. Curr Med Res Opin. 2004; 20: 1501-1510.
16. McCullough PA, Jurkovitz CT, Pergola PE, McGill JB, Brown WW, Collins AJ, Chen SC, Li S, Singh A, Norris KC, Klag MJ, Bakris GL. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007; 167: 1122-1129.
17. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006; 47: S11-145.
18. Rasu RS, Manley HJ, Crawford T, Balkrishnan R. Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data. Clin Ther. 2007; 29: 1524-1534.
19. Schoolwerth AC, Engelgau MM, Hostetter TH, Rufo KH, Chianchiano D, McClellan WM, Warnock DG, Vinicor F. Chronic kidney disease: a public health problem that needs a public health action plan. Prev Chronic Dis. 2006; 3: A57.
20. US Renal Data System. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidey Diseases; 2007; 105: 126-127.
21. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant. 2003; 18: 89-100.
22. Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol. 2006; 17: 2293-2298.
23. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis. 2002; 40: 1153-1161.